Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill
Feb 9, 2026
01:53
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.